Publication:
BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis

dc.contributor.authorRichart, Laia
dc.contributor.authorCarrillo-de-Santa-Pau, Enrique
dc.contributor.authorRío-Machín, Ana
dc.contributor.authorde Andrés, Mónica P
dc.contributor.authorCigudosa, Juan C
dc.contributor.authorLobo, Víctor J Sánchez-Arévalo
dc.contributor.authorReal Arribas, Francisco
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. Comisión Europea. 7 Programa Marco
dc.date.accessioned2019-07-04T11:32:40Z
dc.date.available2019-07-04T11:32:40Z
dc.date.issued2016-01-05
dc.description.abstractc-MYC oncogene is deregulated in most human tumours. Histone marks associated with transcriptionally active genes define high-affinity c-MYC targets. The mechanisms involved in their recognition by c-MYC are unknown. Here we report that c-MYC interacts with BPTF, a core subunit of the NURF chromatin-remodelling complex. BPTF is required for the activation of the full c-MYC transcriptional programme in fibroblasts. BPTF knockdown leads to decreased c-MYC recruitment to DNA and changes in chromatin accessibility. In Bptf-null MEFs, BPTF is necessary for c-MYC-driven proliferation, G1-S progression and replication stress, but not for c-MYC-driven apoptosis. Bioinformatics analyses unveil that BPTF levels correlate positively with c-MYC-driven transcriptional signatures. In vivo, Bptf inactivation in pre-neoplastic pancreatic acinar cells significantly delays tumour development and extends survival. Our findings uncover BPTF as a crucial c-MYC co-factor required for its biological activity and suggest that the BPTF-c-MYC axis is a potential therapeutic target in cancer.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipWe thank the members of the Epithelial Carcinogenesis Group for valuable discussions;N. del Pozo for valuable contributions with animal experimentation; A. Picornell forvaluable contributions in an early phase of the project; M. Soengas for providing cells; M. Magnuson and C. V. Wright for providing mice; B. Amati, M. Beato, O. Fernandez-Capetillo, M. Serrano, G. Vicent and A. Sabo`for providing critical comments to prior versions of the manuscript. This work was supported, in part, by grants from Ministerio de Economıa y Competitividad, Madrid, Spain (SAF2007–60860, SAF2011–29530and ONCOBIO Consolider), Instituto de Salud Carlos III, Madrid, Spain (RTICCRD12/0036/0034), European Union Seventh Framework Programme (grant 256974), and an EIN/Roche-CNIO collaborative grant to F.X.R.; and grants from Instituto de Salud Carlos III (INTRASALUD PI12/00425 and RTICC RD12/0036/0037) to J.C.C.es_ES
dc.format.number1es_ES
dc.format.page10153es_ES
dc.format.volume7es_ES
dc.identifier.citationNat Commun. 2016 ;7:10153.es_ES
dc.identifier.doi10.1038/ncomms10153es_ES
dc.identifier.e-issn2041-1723es_ES
dc.identifier.issn2041-1723es_ES
dc.identifier.journalNature communicationses_ES
dc.identifier.pubmedID26729287es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7856
dc.language.isoenges_ES
dc.publisherNature Publishing Group
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/256974es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2007-60860es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2011-29530es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/ PI12/00425es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD12/0036/0037es_ES
dc.relation.publisherversionhttps://doi.org/10.1038/ncomms10153.es_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Carcinogénesis Epiteliales_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAnimalses_ES
dc.subject.meshAntigens, Nucleares_ES
dc.subject.meshCell Linees_ES
dc.subject.meshCell Proliferationes_ES
dc.titleBPTF is required for c-MYC transcriptional activity and in vivo tumorigenesises_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication62d13a40-e75d-49b1-bb0a-f54a4146ad3e
relation.isAuthorOfPublication.latestForDiscovery62d13a40-e75d-49b1-bb0a-f54a4146ad3e
relation.isFunderOfPublication77b2fc20-6311-4e46-98a7-83e46257b93b
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication453a1d63-c349-4a0e-b0f2-f4edba065c75
relation.isFunderOfPublication.latestForDiscovery77b2fc20-6311-4e46-98a7-83e46257b93b
relation.isPublisherOfPublication301fb00e-338e-4f8c-beaa-f9d8f4fefcc0
relation.isPublisherOfPublication.latestForDiscovery301fb00e-338e-4f8c-beaa-f9d8f4fefcc0

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
BPTFisrequiredforc-MYCtranscriptional_2016.pdf
Size:
2.37 MB
Format:
Adobe Portable Document Format
Description:
Loading...
Thumbnail Image
Name:
Supplementary_BPTFisrequiredforc-MYCtranscriptional_2016_2.zip
Size:
12.18 MB
Format: